Drain fluid may hold key to immunotherapy response in gastroesophageal cancer
NCT ID NCT05338060
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study collected surgical drain fluid and blood from 10 patients who had surgery for stomach or esophageal cancer. Researchers analyzed these samples for molecular markers that might predict how well a patient would respond to immunotherapy. The goal was to establish a method for collecting and studying these fluids, not to test a new treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help identify which patients with gastroesophageal cancer are most likely to benefit from immunotherapy after surgery.
- What could go wrong
- This was a very small, early study (10 participants) focused on collecting samples, not testing a treatment. The findings may not lead to a usable test or apply to larger populations.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROESOPHAGEAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Inova Schar Cancer Institute
Fairfax, Virginia, 22031, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Pulsing radiation may spare esophageal cancer patients from agonizing throat pain
- Can sequencing immunotherapy before chemo boost stomach cancer outcomes?
- Can a less extensive stomach surgery preserve appetite better?
- Drug cocktail aims to shrink Hard-to-Treat stomach cancers
- New study aims to close gaps in cancer care for black patients
- Diet and exercise may boost quality of life for incurable cancer patients